Featuring a patient’s perspective on the Health Research Authority’s transparency consultation, the launch of the Journal of Trial and Error and the call for ResearchGate to educate users on responsible content sharing.
Featuring the use of ‘spin’ in clinical trial abstracts, the first publication in UCL Open: Environment, a new clinical trial educational resource and insights from the OASPA webinar on learned societies and open access.
Featuring the release of the AMWA-EMWA-ISMPP position statement on predatory publishing, the hidden disclosures of medical journal editors, the citation advantage of preprints and the launch of the Open Pharma Calendar of Open Access Events
Featuring the lack of transparency across clinical trials in French hospitals, the introduction of Registered Reports, the data detective who protects patients and one patient advocate’s experience with the medical publishing process
Featuring a summary of the Open Pharma team’s trip to Evidence-Based Medicine Live 2019, the potential use of Literature Programming to improve research transparency, a new data depot project in India and the lack of institutional incentives for researchers to publish open access
Featuring concerns over predatory journals infiltrating PubMed, priorities for Plan S, new guidelines for open peer review and the first full open access agreement for Springer Nature
Featuring the role of the scientific community in maximizing the impact of metadata, the value of plain-language summaries, an alternative open access publishing model and the growing support for Plan U
Featuring new methods for linking data sets to authors, the upcoming launch of medRxiv and a summary of the revised Plan S guidelines.
Featuring the rising tide of article processing charges and preprints, the changes to the ways in which journals are judged and the limited value of social media in increasing the reach of research
Featuring the development of a new evidence framework for discussing hot open science topics that can be used to address misinformation in scientific publishing, the introduction of transparent manuscript-handling processes, and making the costs of clinical trials publicly available.